MétaCan
Menu
Back to cohort
Record W4200171022 · doi:10.1111/jop.13270

Efficacy and safety of a novel mucoadhesive clobetasol patch for treatment of erosive oral lichen planus: A phase 2 randomized clinical trial

2021· article· en· W4200171022 on OpenAlexaffabout
Michael T. Brennan, Lars Siim Madsen, Deborah Saunders, Joel J. Napeñas, Christine McCreary, Richeal Ní Ríordáin, Anne Marie Lynge Pedersen, Stefano Fedele, Richard J. Cook, Rafik Abdelsayed, Maria T. Llopiz, Vidya Sankar, Kevin M. Ryan, Donna A. Culton, Yousra Akhlef, Fausto Castillo, Inti Fernandez, Sabine Jurge, Alexander Ross Kerr, Chad M. McDuffie, Tim McGaw, Alan J. Mighell, Thomas P. Sollecito, Thomas Schlieve, M Carrozzo, Athena Papas, Thomas Bengtsson, Ibtisam Al‐Hashimi, Laurie B. Burke, Nancy W. Burkhart, Shauna Culshaw, Bhavik Desai, J. Mølholm Hansen, Pia Jensen, Torkil Menné, Paras Patel, Martin H. Thornhill, Nathaniel S. Treister, Thomas Ruzicka

Bibliographic record

VenueJournal of Oral Pathology and Medicine · 2021
Typearticle
Languageen
FieldDentistry
TopicOral Health Pathology and Treatment
Canadian institutionsAlberta Hospital EdmontonNOSM UniversityNortheast Cancer CentreHealth Sciences North
FundersUniversity College London Hospitals NHS Foundation TrustNational Institute for Health and Care ResearchInnovationsfonden
KeywordsDermatologyMedicineOral lichen planusRandomized controlled trialSurgery

Abstract

fetched live from OpenAlex

Abstract Background Oral lichen planus (OLP) is a chronic inflammatory disorder of the oral mucosa. Currently there is no approved treatment for OLP. We report on the efficacy and safety of a novel mucoadhesive clobetasol patch (Rivelin ® ‐CLO) for the treatment of OLP. Methods Patients with confirmed OLP and measurable symptomatic ulcer(s) participated in a randomized, double‐blind, placebo‐controlled, multicenter clinical trial testing a novel mucoadhesive clobetasol patch (Rivelin ® ‐CLO) in OLP across Europe, Canada, and the United States. Patients were randomized to placebo (nonmedicated), 1, 5, 20 µg Clobetasol/patch, twice daily, for 4 weeks. The primary endpoint was change in total ulcer area compared to baseline. Secondary endpoints included improvement from baseline in pain, disease activity, and quality of life. Results Data were analyzed and expressed as mean [SD]. One hundred thirty‐eight patients were included in the study; 99 females and 39 males, mean age was 61.1 [11.6] years. Statistical analyses revealed that treatment with 20‐μg Rivelin ® ‐CLO patches demonstrated significant improvement with ulcer area ( p = 0.047), symptom severity ( p = 0.001), disease activity ( p = 0.022), pain ( p = 0.012), and quality of life ( p = 0.003) as compared with placebo. Improvement in OLP symptoms from beginning to the end of the study was reported as very much better (best rating) in the 20‐µg group (25/32) patients compared to the placebo group (11/30), ( p = 0.012). Adverse events were mild/moderate. Candidiasis incidence was low (2%). Conclusions Rivelin ® ‐CLO patches were superior to placebo demonstrating statistically significant, clinically relevant efficacy in objective and subjective improvement and, with a favorable safety profile.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.021

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.002
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0040.002
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0030.002
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.134
GPT teacher head0.475
Teacher spread0.342 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations40
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Oral Pathology and MedicineSame topicOral Health Pathology and TreatmentFrench-language works237,207